This paper includes the ADA’s current recommendations for diabetes care, general treatment goals and guidelines, and quality of care evaluation tools. The guidelines recommend that in patients with established cardiovascular disease, kidney disease, or heart failure, SGLT2 inhibitors or GLP-1 RA should be considered regardless of HbA1c levels. Here, GLP1R is linked to cardiovascular disorder.